Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02421939
Title A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Astellas Pharma Global Development, Inc.
Indications

acute myeloid leukemia

Therapies

Cytarabine

Cytarabine + Fludarabine + Idarubicin

Cytarabine + Etoposide + Mitoxantrone

Azacitidine

Gilteritinib

Filgrastim

Age Groups: adult
Covered Countries USA | CAN

Additional content available in CKB BOOST